Glucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Open accessThe DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments beta cell mass via activation of beta cell proliferation and islet neogenesis. We examined whether GLP-1 receptor signaling modifies the cellular susceptibility to apoptosis. Mice administered streptozotocin (STZ), an agent known to induce beta cell apoptosis, exhibit sustained improvement in glycemic control and increased levels of plasma insulin with concomitant administration of the GLP-1 agonist exendin-4 (Ex-4). Blood glucose remained significantly lower for weeks after cessation of exendin-4. STZ induced beta cell apoptosis, which was significantly reduced by co-administration of Ex-4. Conversely, mice with a targeted disruption of the GLP-1 receptor gene exhibited increased beta cell apoptosis after STZ administration. Exendin-4 directly reduced cytokine-induced apoptosis in purified rat beta cells exposed to interleukin 1beta, tumor necrosis fator alpha, and interferon gamma in vitro. Furthermore, Ex-4-treated BHK-GLP-1R cells exhibited significantly increased cell viability, reduced caspase activity, and decreased cleavage of beta-catenin after treatment with cycloheximide in vitro. These findings demonstrate that GLP-1 receptor signaling directly modifies the susceptibility to apoptotic injury, and provides a new potential mechanism linking GLP-1 receptor activation to preservation or enhancement of beta cell mass in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies to date that have reported an increase in β-cell mass with glucagon-like peptide 1 (GLP-1)-1 based therapies were undertaken in young rodents (17–21).”
From Age-Dependent Decline in β-Cell Proliferation Restricts the Capacity of β-Cell Regeneration in Mice (2009) · cites this paper as [19]
Citations
Cites
Glucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903
Self-citationMojsov, S., Weir, G. C., & Habener, J. F. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112855 · Cited by 882
Induction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationDeacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Self-citationSherwood, N. M., Krueckl, S. L., & McRory, J. E. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0414 · Cited by 726
Research works printed but not linked: 7
- de la Tour, 2001, Mol. Endocrinol., 15, 476
- Boushey, 2001, Cancer Res., 61, 687
- Trumper, 2001, Mol. Endocrinol., 15, 1559
- Drucker, 1997, Am. J. Physiol., 273, G1252
- Drucker, 2001, J. Clin. Endocrinol. Metab., 86, 1759
- Bregenholt, 2001, 50, 125
- Sherwood, 2000, Endocr. Rev., 21, 619
Cited by
Items 301–400 of 597
Chien, C., Fan, S.-C., Lin, S.-C., Kuo, C., Yang, C., Yu, T., Lee, S., Cheng, D.-Y., & Li, P.-C. (2014) · Thrombosis and Haemostasis · doi:10.1160/th14-03-0258 · Cited by 34
ElBatsh, M. M., El‐Batch, M., Shafik, N. M., & Younos, I. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.11.033 · Cited by 31
β-Cell Inactivation of Gpr119 Unmasks Incretin Dependence of GPR119-Mediated Glucoregulation
Panaro, B. L., Flock, G. B., Campbell, J. E., Beaudry, J. L., Cao, X., & Drucker, D. J. (2017) · Diabetes · doi:10.2337/db17-0017 · Cited by 33
Self-citationEarly Manifestations in Multiple-low-dose Streptozotocin-induced Diabetes in Mice
Karabatas, L. M., Pastorale, C., Bruno, L., Maschi, F., Pivetta, O. H., Lombardo, Y. B., Chemes, H., & Basabe, J. C. (2005) · Pancreas · doi:10.1097/01.mpa.0000161888.02244.7a · Cited by 34
Exendin-4 ameliorates renal ischemia-reperfusion injury in the rat
Yang, H., Li, H., Wang, Z., Shi, Y., Jiang, G., & Zeng, F. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.06.042 · Cited by 34
OGAWA, N., Minamimura, K., Kodaka, T., & MAKI, T. (2006) · Journal of Autoimmunity · doi:10.1016/j.jaut.2006.03.001 · Cited by 29
Gut peptides in the treatment of diabetes mellitus
Vahl, T. P., & D’Alessio, D. A. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.3.177 · Cited by 31
Incretins and their role in the management of diabetes
Frías, J. P., & Edelman, S. V. (2007) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0b013e32825ea2ba · Cited by 30
Ding, L., Gysemans, C. A., Stangé, G. M., Heremans, Y., Yuchi, Y., Takiishi, T., Korf, H., Chintinne, M., Carr, R. D., Heimberg, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107935 · Cited by 28
Nucleosome positioning, nucleotide excision repair and photoreactivation in Saccharomyces cerevisiae
Guintini, L., Charton, R., Peyresaubes, F., Thoma, F., & Conconi, A. (2015) · DNA repair · doi:10.1016/j.dnarep.2015.09.012 · Cited by 31
COUP-TFII Controls Mouse Pancreatic β-Cell Mass through GLP-1-β-Catenin Signaling Pathways
Boutant, M., Ramos, O. H. P., Tourrel-Cuzin, C., Movassat, J., Ilias, A., Vallois, D., Planchais, J., Pégorier, J.-P., Schuit, F., Petit, P. X., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030847 · Cited by 28
“GLP-1 protects pancreatic b-cells from apoptosis [20,19] and promotes bcell neogenesis in many rodent model systems and human”
BackgroundBrill, A. L., Wisinski, J. A., Cadena, M. T., Thompson, M. F., Fenske, R. J., Brar, H. K., Schaid, M. D., Pasker, R. L., & Kimple, M. E. (2016) · Molecular Endocrinology · doi:10.1210/me.2015-1164 · Cited by 29
Vahl, T. P., & D’Alessio, D. A. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000078991.96795.84 · Cited by 33
Incretin-based therapies: can we achieve glycemic control and cardioprotection?
Angeli, F. S., & Shannon, R. P. (2013) · Journal of Endocrinology · doi:10.1530/joe-13-0195 · Cited by 30
“Improving glucose control: effect on CV outcomes GLP-1R activation stimulates adenylate cyclase, which increases cAMP, leading to activation of protein kinase A (PKA) and insulin biosyntheses by the b cells (Li et al. 2003).”
BackgroundValidation studies on blood collection from the jugular vein of conscious mice.
Shirasaki, Y., Ito, Y., Kikuchi, M., Imamura, Y., & Hayashi, T. (2012) · PubMed Central · Cited by 27
The ductal origin of structural and functional heterogeneity between pancreatic islets
Merkwitz, C., Blaschuk, O. W., Schulz, A., Lochhead, P. J., Meister, J., Ehrlich, A., & Ricken, A. M. (2013) · Progress in Histochemistry and Cytochemistry · doi:10.1016/j.proghi.2013.09.001 · Cited by 32
Horiuchi, H., Harada, N., Adachi, T., Nakano, Y., Inui, H., & Yamaji, R. (2014) · Journal of Nutritional Science and Vitaminology · doi:10.3177/jnsv.60.291 · Cited by 33
Kakimoto, T., Kimata, H., Iwasaki, S., Fukunari, A., & Utsumi, H. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0456 · Cited by 27
“Several reports have demonstrated an increase in pancreatic insulin-positive b-cells by exendin-4 treatment in animal models of type 2 diabetes (Xu et al. 1999, Stoffers et al. 2000, Tourrel et al. 2001, Wang & Brubaker 2002, Li et al. 2003).”
BackgroundWang, W., Wu, R., Pin, C., Xu, X., Shi, X. Z., Huang, L. H., Shao, Z. L., & Guo, W. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3212 · Cited by 27
New potential treatments for protection of pancreatic B‐cell function in Type 1 diabetes
Cernea, S., & Pozzilli, P. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02556.x · Cited by 30
Making progress: preserving beta cells in type 1 diabetes
GALLAGHER, M. P., Goland, R., & Greenbaum, C. J. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06321.x · Cited by 31
van Genugten, R. E., van Raalte, D. H., & Diamant, M. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(09)70006-3 · Cited by 27
Ghanaat‐Pour, H., & Sjöholm, Å. (2008) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.896 · Cited by 28
Abdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.045 · Cited by 28
Lamont, B. J., & Andrikopoulos, S. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0577 · Cited by 29
Exendin-4 protects rat islets against loss of viability and function induced by brain death
Carlessi, R., Lemos, N. E., Dias, A. L., de Oliveira, F. S., Brondani, L. D. A., Canani, L. H. S., Bauer, A. C., Leitão, C. B., & Crispim, D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.05.009 · Cited by 29
“Such analogs have been shown to prevent β-cell apoptosis triggered by different stimuli such as lipotoxicity, pro-inflammatory cytokines, glucocorticoids and streptozotocin (Ferdaoussi et al., 2008; Li et al., 2003; Natalicchio et al., 2013; Ranta et al., 2006).”
Chen, L., Yao, M., Fan, X., Lin, X., Arroo, R., Silva, A., Sungthong, B., Dragan, S. R., Paoli, P., Wang, S., et al. (2020) · eFood · doi:10.2991/efood.k.200207.001 · Cited by 28
Padrutt, I., Lutz, T. A., Reusch, C. E., & Zini, E. (2015) · Research in Veterinary Science · doi:10.1016/j.rvsc.2014.12.001 · Cited by 25
“GLP-1 leads to an 237 increase of insulin secretion in humans due to direct effects on pancreatic β-cells, including a 238 stimulation of insulin biosynthesis and of β-cell proliferation, as well as enhanced β-cell survival 239 and resistance to apoptosis (Farilla et al., 2003; Li et al., 2003).”
BackgroundSitagliptin: A novel agent for the management of type 2 diabetes mellitus
Pham, D. Q., Nogid, A., & Plakogiannis, R. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070248 · Cited by 28
Kim, P.-H., Lee, M., & Kim, S. W. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.06.010 · Cited by 26
Sulistio, M. S., Carothers, C., Mangat, M., Lujan, M., OLIVEROS, R. A., & CHILTON, R. J. (2009) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0015-9 · Cited by 26
Kaku, K., Kiyosue, A., Ono, Y., Shiraiwa, T., Kaneko, S., Nishijima, K., Bosch‐Traberg, H., & Seino, Y. (2015) · Journal of Diabetes Investigation · doi:10.1111/jdi.12367 · Cited by 27
Iida, A., Seino, Y., Fukami, A., Maekawa, R., Yabe, D., Shimizu, S., Kinoshita, K., Takagi, Y., Izumoto, T., Ogata, H., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3935-2 · Cited by 27
“at a dose of 50 mg (kg body weight [BW]) for five consecutive days (moderate-dose STZ [mSTZ]) [18].”
Therapeutic approaches based on beta-cell mass preservation and/or regeneration
Robert, A. R. (2009) · Frontiers in bioscience · doi:10.2741/3345 · Cited by 26
Mize, D. L. E., & Salehi, M. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0377-9 · Cited by 24
Fang, Y., Jiang, D., Wang, Y., Wang, Q., Lv, D., Liu, J., & Liu, C. (2018) · Drug Development Research · doi:10.1002/ddr.21439 · Cited by 21
“…that GLP-1R has antiapoptotic properties, and studies have also presented that GLP-1 and exendin-4 strengthen cellular integrity and enhance total survival after exposure to fatty acids, cytokines, and peroxides (Harkavyi & Whitton, 2010; Hui, Nourparvar, Zhao, & Perfetti, 2003; Li et al., 2003).”
BackgroundAsakawa, M., Mitsui, H., Akihisa, M., Sekine, T., Niitsu, Y., Kobayashi, A., Miyake, A., Hashimoto, N., Kawamura, M., & Ogawa, Y. (2015) · SpringerPlus · doi:10.1186/s40064-015-1135-z · Cited by 25
Sun, Z., Tong, G., Kim, T. H., Ma, N., Niu, G., Cao, F., & Chen, X. S. (2014) · Theranostics · doi:10.7150/thno.10226 · Cited by 24
“GLP-1(7-36) exerts incretin-like actions stimulating insulin secretion in a glucose-dependent manner when interacting with its receptor (GLP-1R) on β islets [3].”
BackgroundMOLECULAR EVOLUTION OF GPCRS: GLP1/GLP1 receptors
Hwang, J., Yun, S., Moon, M. J., Park, C. R., & Seong, J. Y. (2014) · Journal of Molecular Endocrinology · doi:10.1530/jme-13-0137 · Cited by 26
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Resnick, O., Bril, F., & Beauchamp, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1520313 · Cited by 27
The required beta cell research for improving treatment of type 2 diabetes
Thorens, B. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12096 · Cited by 26
Understanding the Cardiovascular Effects of Incretin
Yoon, J. S., & Lee, H. W. (2011) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2011.35.5.437 · Cited by 26
“GLP-1 administration not only produces weight loss associated with reduced food intake [14,15], but also promotes insulin biosynthesis and β-cell proliferation [16,17].”
BackgroundFujimoto, S., Mukai, E., & Inagaki, N. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.013 · Cited by 24
Taşkıran, E., Erdoğan, M. A., Yiğittürk, G., & Erbaş, O. (2019) · Cardiovascular Toxicology · doi:10.1007/s12012-019-09524-x · Cited by 25
Delmeire, D., Flamez, D., Moens, K., Hinke, S. A., Schravendijk, C. V., PIPELEERS, D. G., & Schuit, F. C. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.035 · Cited by 24
Омаровна, К. И., Zhernakova, Y. V., & Blinova, N. V. (2023) · Systemic Hypertension · doi:10.38109/2075-082x-2022-4-37-44 · Cited by 24
Pinto, S., Viegas, J. S. R., Cristelo, C., Pacheco, C., Barros, S., Buckley, S. T., Garousi, J., Gräslund, T., Santos, H. A., & Sarmento, B. F. C. C. (2024) · ACS Nano · doi:10.1021/acsnano.4c11172 · Cited by 22
Juang, J., Kuo, C.-H., Wu, C., & Juang, C. (2008) · Cell Transplantation · doi:10.3727/096368908786092766 · Cited by 25
Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas
Gezginci-Oktayoğlu, S., & Bolkent, Ş. (2009) · Biochemistry and Cell Biology · doi:10.1139/o09-046 · Cited by 23
“Recent data show that the actions of GLP-1 that protect against diabetes include the enhancement of beta cell mass in rodents through inhibition of beta cell apoptosis and stimulation of beta cell proliferation and islet neogenesis (Li et al. 2003).”
BackgroundMethodGLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated β-cell damage in Akita mice
Yamane, S., Hamamoto, Y., Harashima, S., Harada, N., Hamasaki, A., Toyoda, K., Fujita, K., Joo, E., Seino, Y., & Inagaki, N. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00075.x · Cited by 23
Keshava, H. B., Mowla, A., Heinberg, L. J., Schauer, P. R., Brethauer, S. A., & Aminian, A. (2017) · Medical Hypotheses · doi:10.1016/j.mehy.2017.05.002 · Cited by 22
Anti-inflammatory effects of GLP-1 in patients with COVID-19
Sazgarnejad, S., Yazdanpanah, N., & Rezaei, N. (2022) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1964955 · Cited by 21
Jin, J., Kang, H.-M., Jung, J., Jeong, J.-W., & Park, C. (2014) · NeuroReport · doi:10.1097/wnr.0000000000000046 · Cited by 21
Liraglutide attenuates partial warm ischemia-reperfusion injury in rat livers
Abdelsameea, A. A., Abbas, N. A. T., & Raouf, S. M. A.-E. (2016) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-016-1330-7 · Cited by 23
“They found inhibition of caspase activation with cytoprotection by GLP-1 receptor stimulation (During et al. 2003; Li et al. 2003).”
Exendin-4 does not modify growth or apoptosis of human colon cancer cells
Wenjing, H., Yu, S., Weisong, L., & Hai-peng, X. (2017) · Endocrine Research · doi:10.1080/07435800.2017.1292525 · Cited by 24
Hussien, N. I., Sorour, S. M., Elkerdasy, H., & Abdelrahman, B. A. (2018) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12944 · Cited by 22
Fernández‐Millán, E., & Guillén, C. (2022) · Biomolecules · doi:10.3390/biom12010104 · Cited by 30
Liraglutide for treating type 1 diabetes
Dejgaard, T. F., Frandsen, C. S., Holst, J. J., & Madsbad, S. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1160050 · Cited by 22
Can we make surrogate β-cells better than the original?
Weir, G. C. (2004) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2004.02.004 · Cited by 21
Xue, S., Wasserfall, C. H., Parker, M., McGrail, S., MCGRAIL, K. M., Campbell‐Thompson, M., Schatz, D., Atkinson, M. A., & Haller, M. J. (2009) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2008.12.004 · Cited by 22
Commonalities of genetic resistance to spontaneous autoimmune and free radical-mediated diabetes
Chen, J., Lu, Y., Lee, C., Li, R., Leiter, E. H., & Mathews, C. E. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.07.020 · Cited by 20
Towards PET Imaging of Intact Pancreatic Beta Cell Mass: A Transgenic Strategy
McGirr, R., Hu, S. L., Yee, S., Kovacs, M. S., Lee, T., & Dhanvantari, S. (2010) · Molecular Imaging and Biology · doi:10.1007/s11307-010-0435-5 · Cited by 20
“low-dose regimen: 40 mg/kg once per day for 5 days [21–23].”
Kuo, C.-C., Chuang, M., Li, C., Tsai, Y., Huang, P., Kuo, H., & Lai, C.-C. (2025) · Diabetologia · doi:10.1007/s00125-025-06453-z · Cited by 23
Tamaki, M., Fujitani, Y., Uchida, T., Hirose, T., Kawamori, R., & Watada, H. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00044.x · Cited by 22
New therapies for type 2 diabetes based on glucagon-like peptide 1.
Salehi, M., & D’Alessio, D. A. (2006) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.73.4.382 · Cited by 23
Palmer, A. J., Roze, S., Valentine, W. J., Minshall, M. E., Lammert, M., Oglesby, A. K., Hayes, C., & Spinas, G. A. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904x2024 · Cited by 19
Murakami, T., Fujimoto, H., Fujita, N., Hamamatsu, K., Matsumoto, K., & Inagaki, N. (2019) · Endocrinology · doi:10.1210/en.2019-00556 · Cited by 18
RetractedShida, T., Kamei, N., Takeda‐Morishita, M., Isowa, K., & Takayama, K. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.04.029 · Cited by 18
Matsuyama‐Yokono, A., Tahara, A., Nakano, R., Someya, Y., Shiraki, K., Hayakawa, M., & Shibasaki, M. (2009) · Metabolism · doi:10.1016/j.metabol.2008.10.012 · Cited by 19
Assessment of Changes in Body Composition After 3 Months of Dulaglutide Treatment
Chen, S., Wang, X., Jin, Y., Chen, X., Song, Q., Wei, G., & Li, L. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s443631 · Cited by 20
Protection of pancreatic β-cells against glucotoxicity by short-term treatment with GLP-1
Park, S.-H., Park, J., Shim, H. M., Na, A., Bae, K.-C., Lim, J.-G., & Song, D. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.02.139 · Cited by 20
GLP-1-related proteins attenuate the effects of mitochondrial membrane damage in pancreatic β cells
Ogata, M., Iwasaki, N., Ide, R., Takizawa, M., & Uchigata, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.03.143 · Cited by 17
“GLP-1 analogs were also shown to prevent apoptosis in vivo [8,9], in which restoration of mitochondrial membrane damage may be involved [10].”
BackgroundZhang, L., Song, X., Zhou, L., Liang, G., Xu, H., Wang, F., Huang, F., & Jiang, G. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0194-9 · Cited by 18
Gluco-Incretins Regulate Beta-Cell Glucose Competence by Epigenetic Silencing of Fxyd3 Expression
Vallois, D., Niederhäuser, G., Ibberson, M. R., Nagaray, V., Marselli, L., Marchetti, P., Chatton, J., & Thorens, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103277 · Cited by 21
“[5,6], and increase their glucose competence [7].”
Vedtofte, L., Bödvarsdóttir, T., Gotfredsen, C. F., Karlsen, A. E., Knudsen, L. B., & Heller, R. S. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.12.005 · Cited by 17
Zheng, W., Li, L., & Li, H. (2021) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114817 · Cited by 16
Bohman, S., Waern, I., Andersson, A., & King, A. (2007) · Cell Transplantation · doi:10.3727/000000007783464452 · Cited by 17
Neuroprotective Effects of rhGLP‐1 in Diabetic Rats with Cerebral Ischemia/Reperfusion Injury
Jiang, D., Wang, Y., Zang, Y., Liu, X., Zhao, L., Wang, Q., Liu, C., Feng, W., Yin, X., & Fang, Y. (2016) · Drug Development Research · doi:10.1002/ddr.21297 · Cited by 17
“GLP-1 and exendin-4 protect PC12 cells against growth factors, glutamate, and b-amyloid [Perry et al., 2002b, 2003] and strengthen cellular integrity and total survival after exposure to fatty acids, cytokines, and peroxides [Hui et al., 2003; Li et al., 2003; Harkavyi and Whitton, 2010].”
BackgroundSiba, I. P., Bortolanza, M., Vital, M. A. B. F., Andreatini, R., da Cunha, J. M., Bel, E. A. D., & Zanoveli, J. M. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.03.008 · Cited by 18
“Since GLP-1 stimulates the proliferation and preservation of pancreatic beta-cells [68,69], it is plausible to hypothesize that the hypoglycemic effect of fish oil may be related to augment of GLP-1.”
Allen, C. H. G., Mervin, L., Mahmoud, S. Y., & Bender, A. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0356-5 · Cited by 16
Sato, T., Hayashi, H., Hiratsuka, M., & Hirasawa, N. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.02.014 · Cited by 15
Physiological and pharmacological actions of glucagon like peptide-1 (GLP-1) in domestic animals
Model, J. F. A., Rocha, D. S., Fagundes, A. D. C., & Vinagre, A. S. (2022) · Veterinary and Animal Science · doi:10.1016/j.vas.2022.100245 · Cited by 18
Exenatide reverses dysregulated microRNAs in high-fat diet-induced obese mice
Lee, I. S., Park, K. C., Yang, K., Choi, H., Jang, Y. S., Lee, J. M., & Kim, H. S. (2015) · Obesity Research & Clinical Practice · doi:10.1016/j.orcp.2015.07.011 · Cited by 16
“Further, exenatide decreases -cell apoptosis and promotes cell growth and survival [7—9].”
BackgroundTherapeutic gene delivery using bioreducible polymers
Ryu, K., & Kim, T. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0275-3 · Cited by 16
“(Ahrén 2011; Brubaker 2010; Li et al. 2003).”
Ansarullah, M., Free, C., Christopherson, J., Chen, Q., Gao, J., Liu, C., Naji, A., Rabinovitch, A., & Guo, Z. (2016) · Journal of Diabetes Research · doi:10.1155/2016/1620821 · Cited by 17
Srivastava, S., Pandey, H. K., Singh, S. K., & Tripathi, Y. B. (2019) · BioScience Trends · doi:10.5582/bst.2019.01181 · Cited by 15
Roges, O. A., Baron, M., & Philis‐Tsimikas, A. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.705 · Cited by 15
GLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Panfili, E., Frontino, G., & Pallotta, M. T. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1171091 · Cited by 16
The transcription factor E2F1 controls the GLP-1 receptor pathway in pancreatic β cells
Bourouh, C., Courty, É., Rolland, L., Pasquetti, G., Gromada, X., Rabhi, N., Carney, C., Moreno, M., Boutry, R., Caron, É., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111170 · Cited by 15
Barakat, G. M., Moustafa, M. E., Khalifeh, I. M., Hodroj, M. H., Bikhazi, A. B., & Rizk, S. E. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-017-0565-1 · Cited by 16
Unmet needs among patients with Type 2 diabetes and secondary failure to oral anti-diabetic agents
Pitocco, D., Valle, D. D. L. N. M., Rossi, A., & Gentilella, R. (2008) · Journal of Endocrinological Investigation · doi:10.1007/bf03346373 · Cited by 14
Linnemann, A. K., & Davis, D. B. (2016) · Journal of Diabetes Investigation · doi:10.1111/jdi.12465 · Cited by 14
Chen, D., Xiang, J.-N., & Yang, L. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.08.072 · Cited by 17
Moon, J. H., Choe, H. J., & Lim, S. K. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14221 · Cited by 15
“Moreover, GLP-1 receptor activation has demonstrated protective effects against b -cell apoptosis 67,68 .”
BackgroundTreatment of diabetes with glucagon-like peptide-1 gene therapy
Riedel, M. J., & Kieffer, T. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.532786 · Cited by 14
Hou, G., Li, C.-N., Liu, S., Huan, Y., Liu, Q., Sun, S., Li, L., Hou, S.-C., & Shen, Z. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.010 · Cited by 14
Molecularly Engineered Islet Cell Clusters for Diabetes Mellitus Treatment
Yook, S., Jeong, J.-H., Jung, Y., Hong, S.-W., Im, B., Seo, J., Park, J. B., Lee, M., Ahn, C., Lee, H., et al. (2012) · Cell Transplantation · doi:10.3727/096368912x640628 · Cited by 12
Nakashima, K., Shimoda, M., Hamamoto, S., Tatsumi, F., Hirukawa, H., Tawaramoto, K., Kanda, Y., & Kaku, K. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.11.008 · Cited by 14
Biology and therapeutic potential of GLP-1 in the treatment of diabetes
Chia, C. W., & Egan, J. M. (2005) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2005.08.013 · Cited by 14
Nutrient regulation of pancreatic β-cell function in diabetes: problems and potential solutions
Flatt, P. R., & Green, B. D. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340774 · Cited by 14
Metadata
- Authors
- Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J.
- Affiliations
- University of Toronto (CA)
- Corresponding author
- Drucker, Daniel J.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-01
- Volume
- 278
- Issue
- 1
- Pages
- 471-478
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2149502431
- Cited by
- 589
- References
- 64
- Citations by year
- 2026: 7 · 2025: 14 · 2024: 9 · 2023: 6 · 2022: 10 · 2021: 12 · 2020: 7 · 2019: 17 · 2018: 7 · 2017: 16 · 2016: 26 · 2015: 34 · 2014: 41 · 2013: 45 · 2012: 33
- FWCI
- 26.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6497 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
- Keywords
- GLP-1 receptor, beta-cell apoptosis, exendin-4, streptozotocin, beta-cell mass, cytokine-induced apoptosis, IL-1β, TNF-α, interferon-gamma, caspase activity, GLP-1 receptor signaling, type 1 diabetes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Cell Survival, Cycloheximide, Cytoskeletal Proteins, Diabetes Mellitus, Experimental, Colforsin, Glucagon, Glucose Tolerance Test, Cricetinae, Insulin, Islets of Langerhans, Male, Mice, Inbred C57BL, Peptide Fragments, Peptides, Protein Precursors, Protein Synthesis Inhibitors, Streptozocin, Venoms, Signal Transduction, Trans-Activators, Cytokines, Rats, Wistar, Apoptosis, Receptors, Glucagon, Mice, Knockout, In Situ Nick-End Labeling, beta Catenin, Mice, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.